Key result
Engineered heart tissues harboring the DSP-R451G mutation exhibited a hypocontractile phenotype with significantly lower peak force (86 µN vs 142 µN) and shortened resting sarcomere length.
Why the study?
A comprehensive mechanism linking DSP mutations to ventricular dilation and heart failure in desmoplakin cardiomyopathy remains elusive.
Absolute Event Rate: 86% vs 142%
p-value: p=0.0002
Desmoplakin haploinsufficiency causes hypocontractility and ventricular dilation via PKC-dependent shortening of resting sarcomere length, which can be rescued by PKC inhibition.
May support inflammation-focused management in DSP cardiomyopathy; leaves open prospective validation before practice change.
Background Mutations in DSP , which encodes the protein desmoplakin, lead to cardiomyopathy with unusually high penetrance. Clinical features include ventricular tachyarrhythmias, fibro-fatty infiltration of both ventricles, and ultimately dilated cardiomyopathy. While some data have been gathered to explain the electrophysiological and contractile consequences of desmoplakin cardiomyopathy, a comprehensive mechanism linking DSP mutations to ventricular dilation and heart failure remains elusive. Methods We use iPSC-derived engineered heart tissue (EHT) bearing a functional desmoplakin haploinsufficiency to model the heart failure phenotype that occurs in desmoplakin cardiomyopathy. Functional haploinsufficiency is secondary to a missense mutation, R451G, that results in proteolytic degradation of desmoplakin with no detectable protein. We complement functional data obtained in tissue-engineered constructs with cell biology assays in 2D cardiomyocytes to glean insights into the mechanism and mechanobiology of desmoplakin cardiomyopathy. Results Engineered heart tissues harboring a desmoplakin insufficiency recapitulate a patient phenotype notable for hypocontractility and ventricular dilation. Surprisingly, DSP-mutant tissues exhibited a shortened resting sarcomere length that was dependent on protein kinase C activity. Concurrently, mechanical load on α-catenin was increased, suggesting a mechanism by which desmosomal insufficiency redistributes force to adherens junctions. Excessive loading on adherens junctions may act as a stimulus for avid insertion of series sarcomeres, shortening the length per sarcomere, and resulting in a contractile deficit. PKC inhibition rescues shortened sarcomere length in DSP- mutant tissues, suggesting that it could be a target for future molecular therapies. Conclusions Our study uncovers a novel mechanism underlying systolic dysfunction in desmoplakin cardiomyopathy. We not only recapitulate the disease phenotype, but we identify sarcomere length regulation through altered force transmission at the intercalated disc as a previously-unrecognized mechanism.
No takes yet. Share an insight, caveat, or question.
Gokhan et al. (2025) studied Desmoplakin cardiomyopathy (Arrhythmogenic cardiomyopathy). DSP-R451G mutation vs. Isogenic wild-type control was evaluated on Isometric twitch peak force (µN) (p=0.0002). Engineered heart tissues harboring the DSP-R451G mutation exhibited a hypocontractile phenotype with significantly lower peak force (86 µN vs 142 µN) and shortened resting sarcomere length.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: